"
Team:Westminster/Team
From 2012.igem.org
| Line 16: | Line 16: | ||
color: #666666; | color: #666666; | ||
} | } | ||
| - | h1 { | + | h1, h2 { |
color: #ff0000; | color: #ff0000; | ||
font-size: 18pt; | font-size: 18pt; | ||
margin-bottom: 0.5em; | margin-bottom: 0.5em; | ||
| + | } | ||
| + | h2 { | ||
| + | font-size: 16pt; | ||
} | } | ||
p { | p { | ||
| Line 135: | Line 138: | ||
<div id="navigation"> | <div id="navigation"> | ||
<ul id="navigation-list"> | <ul id="navigation-list"> | ||
| - | <li><a href="https://2012.igem.org/Team:Westminster" class="navlink | + | <li><a href="https://2012.igem.org/Team:Westminster" class="navlink">Home</a></li> |
| - | <li><a href="https://2012.igem.org/Team:Westminster/Team" class="navlink">Team</a></li> | + | <li><a href="https://2012.igem.org/Team:Westminster/Team" class="navlink active">Team</a></li> |
<li><a href="https://igem.org/Team.cgi?year=2012&team_name=Westminster"class="navlink">Team Profile</a></li> | <li><a href="https://igem.org/Team.cgi?year=2012&team_name=Westminster"class="navlink">Team Profile</a></li> | ||
<li class="submenu-holder"> | <li class="submenu-holder"> | ||
| Line 164: | Line 167: | ||
</div><!-- #home-main-image --> | </div><!-- #home-main-image --> | ||
| - | <div id="home-main-text | + | <div id="home-main-text"> |
| - | < | + | <h2>Lorem Ipsum</h2> |
<p>Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.</p> | <p>Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.</p> | ||
| - | + | <h2>Lorem Ipsum</h2> | |
<p>The Westminster iGEM 2012 team aims to combat cancer recurrence by using one key feature of CSCs – increased Aldehyde Dehydrogenase (ALDH) activity. We have used the promoters of 4 different ALDH isoforms present in aggressive forms of cancer to design 3 constucts that will allow us to identify, isolate and eliminate CSC, offering a novel tool for the study of this cells and a potential new anti-cancer therapy for the future.</p> | <p>The Westminster iGEM 2012 team aims to combat cancer recurrence by using one key feature of CSCs – increased Aldehyde Dehydrogenase (ALDH) activity. We have used the promoters of 4 different ALDH isoforms present in aggressive forms of cancer to design 3 constucts that will allow us to identify, isolate and eliminate CSC, offering a novel tool for the study of this cells and a potential new anti-cancer therapy for the future.</p> | ||
</div><!-- #home-main-text --> | </div><!-- #home-main-text --> | ||
Revision as of 19:33, 25 September 2012
Lorem Ipsum
Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.
Lorem Ipsum
The Westminster iGEM 2012 team aims to combat cancer recurrence by using one key feature of CSCs – increased Aldehyde Dehydrogenase (ALDH) activity. We have used the promoters of 4 different ALDH isoforms present in aggressive forms of cancer to design 3 constucts that will allow us to identify, isolate and eliminate CSC, offering a novel tool for the study of this cells and a potential new anti-cancer therapy for the future.
